A New Class of Therapeutics for Multiple Tumor Types
A new dual targeting small molecule for the treatment of multiple tumors with selective tumor growth inhibition and activation of cell programmed cell death, all the while acting on two primary cancer drug resistance domains.
Science
Based on the cancer research of Dr. Peter Crooks and vetted by proprietary Artificial Intelligence based platforms
Molecule
Botanically based with known and tested safety profiles, patent protected, synthesized and tested
Therapeutic Targets
Broad applicability toward multiple tumor types affecting both pediatric and adult malignancies as per National Cancer Institute testing
Investors
Want to know more?